These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10326547)

  • 21. Targeting the prostate-specific membrane antigen for prostate cancer therapy.
    Bühler P; Wolf P; Elsässer-Beile U
    Immunotherapy; 2009 May; 1(3):471-81. PubMed ID: 20635963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
    Tjoa B; Boynton A; Kenny G; Ragde H; Misrock SL; Murphy G
    Prostate; 1996 Jan; 28(1):65-9. PubMed ID: 8545283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of PSA mRNA and PSMA mRNA by RT-PCR].
    Deguchi T; Ehara H; Takahashi Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():151-5. PubMed ID: 12599562
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM).
    Weissensteiner T
    Nucleic Acids Res; 1998 Jan; 26(2):687. PubMed ID: 9480454
    [No Abstract]   [Full Text] [Related]  

  • 26. [The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].
    Zeng H; Li H; Liao YC; Li X; Wu Q; Yang YR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):169-71. PubMed ID: 15807257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Construction and expression of recombinant plasmid with prostate-specific membrane antigen promoter and enhancer regulating uracil phosphoribosyltransferase gene].
    Zhao FJ; Li H; Cheng HM; Zeng H; Wei Q; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):172-5. PubMed ID: 15807258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific membrane antigen.
    Fair WR; Israeli RS; Heston WD
    Prostate; 1997 Jul; 32(2):140-8. PubMed ID: 9215402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
    Israeli RS; Miller WH; Su SL; Powell CT; Fair WR; Samadi DS; Huryk RF; DeBlasio A; Edwards ET; Wise GJ
    Cancer Res; 1994 Dec; 54(24):6306-10. PubMed ID: 7527294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].
    Tang QL; Yao MY
    Zhonghua Nan Ke Xue; 2008 Jan; 14(1):79-82. PubMed ID: 18297820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review).
    Ullah K; Addai Peprah F; Yu F; Shi H
    Oncol Rep; 2018 Dec; 40(6):3136-3143. PubMed ID: 30542701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
    Lu J; Celis E
    Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific membrane antigen: present and future applications.
    Chang SS; Gaudin PB; Reuter VE; Heston WD
    Urology; 2000 May; 55(5):622-9. PubMed ID: 10792065
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prostatic markers, today and tomorrow].
    Terrone C; Faraone N; Aimo G; Priolo G
    Recenti Prog Med; 2000 Nov; 91(11):576-80. PubMed ID: 11125951
    [No Abstract]   [Full Text] [Related]  

  • 35. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.
    Lodge PA; Jones LA; Bader RA; Murphy GP; Salgaller ML
    Cancer Res; 2000 Feb; 60(4):829-33. PubMed ID: 10706088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical characterization of human glutamate carboxypeptidase III.
    Hlouchová K; Barinka C; Klusák V; Sácha P; Mlcochová P; Majer P; Rulísek L; Konvalinka J
    J Neurochem; 2007 May; 101(3):682-96. PubMed ID: 17241121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer.
    Clements JA; Rohde P; Allen V; Hyland VJ; Samaratunga ML; Tilley WD; Lavin MF; Gardiner RA
    J Urol; 1999 Apr; 161(4):1337-43. PubMed ID: 10081904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostate specific membrane antigen (PSMA) as a role of tumor marker].
    Saito S; Horiguchi Y; Murai M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():145-50. PubMed ID: 12599561
    [No Abstract]   [Full Text] [Related]  

  • 40. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles.
    Nelson PS
    Ann N Y Acad Sci; 2002 Dec; 975():232-46. PubMed ID: 12538168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.